Akelos
New York
About Akelos
Akelos is a biopharmaceutical company that focuses on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. It was founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs. The company was founded in 2018 and is based in New York, NY, United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.1M
- Funding stage: Seed
- Last round: Grant (Jan 2020)
- Website: akelosinc.com
- Phone: (212) 953-1544
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/akelos-147646 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.